Beigene (NASDAQ:BGNE) Rating Reiterated by Maxim Group

Maxim Group reiterated their buy rating on shares of Beigene (NASDAQ:BGNE) in a report published on Tuesday morning, AnalystRatings.com reports. The brokerage currently has a $210.00 target price on the stock.

Several other research analysts have also recently issued reports on the company. Piper Jaffray Companies reissued a buy rating and issued a $230.00 target price (up from $200.00) on shares of Beigene in a research report on Friday, November 15th. UBS Group cut shares of Beigene from a buy rating to a neutral rating in a report on Tuesday, November 19th. Cowen lifted their price target on shares of Beigene from $170.00 to $225.00 and gave the stock an outperform rating in a research note on Wednesday, November 13th. Zacks Investment Research downgraded shares of Beigene from a strong-buy rating to a hold rating in a research report on Tuesday, November 5th. Finally, ValuEngine downgraded Beigene from a strong-buy rating to a buy rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $208.00.

BGNE stock opened at $181.02 on Tuesday. The company has a market cap of $8.77 billion, a P/E ratio of -14.90 and a beta of 1.18. Beigene has a 1 year low of $108.00 and a 1 year high of $210.35. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.40 and a quick ratio of 5.26. The stock’s fifty day moving average price is $183.97 and its 200-day moving average price is $142.47.

Beigene (NASDAQ:BGNE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($5.11) EPS for the quarter, missing analysts’ consensus estimates of ($3.56) by ($1.55). The firm had revenue of $50.14 million for the quarter, compared to analysts’ expectations of $65.43 million. Beigene had a negative net margin of 192.75% and a negative return on equity of 53.11%. The firm’s revenue was down 7.5% compared to the same quarter last year. During the same quarter last year, the company posted ($2.53) EPS. As a group, analysts expect that Beigene will post -12.85 earnings per share for the current year.

In other Beigene news, CFO Howard Liang sold 25,000 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $194.34, for a total value of $4,858,500.00. Following the completion of the sale, the chief financial officer now owns 122,317 shares in the company, valued at approximately $23,771,085.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Jane Huang sold 1,500 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $194.49, for a total value of $291,735.00. Following the sale, the chief marketing officer now directly owns 291,667 shares in the company, valued at $56,726,314.83. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 73,704 shares of company stock worth $14,139,047. 10.70% of the stock is owned by company insiders.

Institutional investors have recently made changes to their positions in the company. Capital Investment Advisory Services LLC purchased a new stake in shares of Beigene during the second quarter worth about $26,000. Ladenburg Thalmann Financial Services Inc. boosted its stake in Beigene by 24.8% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 443 shares of the company’s stock valued at $55,000 after buying an additional 88 shares during the last quarter. Riverhead Capital Management LLC grew its holdings in Beigene by 28.6% during the 2nd quarter. Riverhead Capital Management LLC now owns 450 shares of the company’s stock valued at $56,000 after buying an additional 100 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in Beigene during the 3rd quarter valued at approximately $58,000. Finally, Tower Research Capital LLC TRC grew its holdings in Beigene by 1,500.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 592 shares of the company’s stock valued at $73,000 after buying an additional 555 shares in the last quarter.

Beigene Company Profile

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Read More: What is the Nikkei 225 index?    

Analyst Recommendations for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit